logo
U.S. drug deaths plunged in 2024. Trump cuts may reverse that, experts warn.

U.S. drug deaths plunged in 2024. Trump cuts may reverse that, experts warn.

Washington Post14-05-2025

U.S. drug deaths plunged in 2024, according to federal data published Wednesday, offering hope that public health measures are paying off even as the toll remains high.
Though there doesn't seem to be a single variable to attribute to the gains, the drop in overdose deaths comes amid concerns that cuts to federal public health agencies and proposals to cut Medicaid could undercut progress.
An estimated 80,391 people died from drugs in 2024, a decrease of nearly 27 percent from the previous year, according to provisional state data collected by the Centers for Disease Control and Prevention. Deaths from synthetic opioids — chiefly fentanyl, which has fueled the overdose crisis during the past decade — played a role in the majority of drug deaths but tumbled by nearly 28,000 fatalities, the estimates show.
The progress comes after drug deaths, which had been rising for more than a decade, soared to staggering levels during the coronavirus pandemic, surpassing 100,000 each year starting in 2021.
'I would characterize this as a historically significant decrease in overdose deaths,' said Brandon Marshall, a Brown University School of Public Health epidemiologist who studies overdose trends. 'We're really seeing decreases almost across the entire nation at this point.'
The data published Wednesday charts a dramatic decline in deaths during then-President Joe Biden's final year in office. The Trump administration has espoused hard-line rhetoric on fentanyl, declaring traffickers a top national security threat and citing them as a key reason for launching trade battles with China and allies Canada and Mexico.
The administration has also touted large fentanyl seizures and asked Mexico to allow the U.S. military to conduct counternarcotics operations on Mexican soil, a request denied by that country's president.
The CDC, in a statement, noted that Trump during his first administration declared the opioid crisis a public-health emergency in 2017. The declines since 2023 are a 'strong sign that public health interventions are making a difference and having a meaningful impact,' the agency said. 'Despite these overall improvements, overdose remains the leading cause of death for Americans aged 18-44, underscoring the need for ongoing efforts to maintain this progress.'
The White House Office of National Drug Control Policy, in an April statement of policy priorities, emphasized curbing the flow of illicit fentanyl, along with expanding access to treatment and research into cutting-edge technologies to identify and address emerging drug threats.
But public health advocates are raising alarm that the Trump administration is undercutting those goals with plans to gut federal funding that helps states pay for overdose antidotes, addiction treatment and other measures. A survey conducted by the nonprofit research firm Rand published in May suggests that more people may be using illicit opioids than previously estimated, underscoring the need for better monitoring.
In a letter to Congress on Monday, more than 300 academics warned that the Trump administration's proposed cuts to the Substance Abuse and Mental Health Services Administration and CDC could 'undermine the hard-fought progress we have made, especially in overdose prevention.'
Experts also worry Republican plans to slash Medicaid could leave former drug users without access to medication, forcing them to turn to street drugs, said Chad Sabora, a drug policy expert who helped organize the letter. 'It will equal more people dying,' he said.
The opioid crisis began decades ago with highly addictive prescription pain killers flooding states. Users later turned to cheaper street heroin, which was largely replaced by fentanyl manufactured by Mexican organized crime groups with precursor chemicals sourced from China. The synthetic drug can be up to 50 times more potent than heroin.
No single reason explains the sudden drop in deaths, researchers and health officials stress.
The Biden administration credited seizures of fentanyl at the southern border, arrests of high-level Mexican drug traffickers and cooperation from Beijing to crack down on unscrupulous Chinese companies exporting precursor chemicals. The administration also expanded access to addiction treatment medications such as buprenorphine, which wards off opioid withdrawals, and the overdose reversal drug naloxone. It also embraced harm reduction organizations that have saturated communities with free naloxone, fentanyl test strips and sterile needles to users.
Fewer deaths 'don't just happen overnight. And that's why we can credit them to the Biden administration's work,' said Sheila P. Vakharia, deputy director of research and academic engagement for the nonprofit Drug Policy Alliance.
Experts also believe that the illicit drug supply, at least in some regions, may be shifting to include less fentanyl. Other drugs added to fentanyl — such as the tranquilizer xylazine — may prolong the sedating effect and stave off opioid withdrawal so that users consume less fentanyl each day, researchers theorize.
Declines in deaths may also reflect the grim reality that fentanyl has killed so many regular users that there are fewer people at risk of overdose. The trajectory of deaths 'can't keep going up. It has essentially to kind of burn itself out,' said Caleb Banta-Green, an addiction expert and drug researcher at the University of Washington School of Medicine.
During Biden's first three years, the death toll topped 100,000 each year.
Deaths during a 12-month period peaked in June 2023 at a staggering 114,670, making the rapid drop nationally all the more remarkable, said Nabarun Dasgupta, an epidemiologist at the University of North Carolina at Chapel Hill. He stressed that deaths had been falling in certain regions where fentanyl had been entrenched for longer.
'Americans have responded to the overdose crisis with powerful community efforts, from every small town to large city. What we are seeing is the fruit of all that collective labor. These local efforts are the heart of overdose prevention,' Dasgupta said.
The CDC data released on Wednesday is not definitive; final death statistics lag because toxicology testing often takes months to complete.
Deaths involving stimulants such as methamphetamine and cocaine — which users increasingly take alongside fentanyl — also decreased, the statistics show.
Two states, Nevada and South Dakota notched slight increases from the previous year. But nearly all states showed declines in 2024. States such as New Hampshire, West Virginia and Ohio recorded declines of 35 percent or more.
In Washington state, where fentanyl became entrenched years later than on the East Coast, suspected drug deaths dropped by nearly 12 percent, after years of increases, for a total of 3,167.
In King County, home to Seattle, health officials distributed 124,700 naloxone kits in 2024 and opened three vending machines for people to obtain the medication, fentanyl test strips and other supplies. County officials and the University of Washington Department of Emergency Medicine also debuted a hotline for doctors to prescribe buprenorphine through free telehealth sessions at any time of day. The city's mayor in August announced an investment of nearly $3 million in opioid litigation settlement money to increase capacity for inpatient treatment.
But the state health department's top medical officer, Tao Kwan-Gett, urged cautioned. Washington overdose deaths fell through much of 2024 but spiked during the final four months of the year.
'It's too early to say that we're seeing a sustained decrease,' Kwan-Gett said. 'I certainly hope we are, but I think we have to continue being vigilant.'
The encouraging statistics in Washington and nationwide belie the heartbreak of addiction — and death.
Among the victims nationwide in 2024: a 17-month-old Los Angeles boy who ingested fentanyl during a child welfare-monitored visit with his mother; a 15-year-old girl who fatally overdosed on fentanyl at her Georgia high school, nine people who fatally overdosed in Austin, during one day.
In Seattle, former movie set designer Wade Paradise battled an opioid addiction for years after taking prescription pain killers. He was largely estranged from his family, living in squalor and suffering from myriad ailments, according to his daughter, Nathalie Paradise, 24.
She said Wade Paradise had struggled to get addiction treatment because of problems with health insurance. In December, he died at age 68 in his home from a pill made of fentanyl. His death received little attention but for Nathalie's GoFundMe page in which she recalled cherished childhood memories of summer swims in a lake and bargain hunting at thrift stores — and detailed his addiction.
'I didn't want it to be a secret anymore. I felt like the people in his life deserved to know the truth,' she said in an interview. 'I also have a lot of friends who use drugs, and I hoped that by sharing my story, it might encourage them to stop.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fast Five Quiz: Opioid Use Disorder
Fast Five Quiz: Opioid Use Disorder

Medscape

time16 minutes ago

  • Medscape

Fast Five Quiz: Opioid Use Disorder

Opioid use disorder (OUD) currently impacts approximately 16 million people worldwide. It is considered a significant public health issue, with experts noting a 'burden that is increasing' globally. As research into optimal management of OUD evolves, updates to clinical guidelines emphasize a more individualized approach to pharmacologic treatment, psychosocial support, and special considerations for specific patient populations, such as pregnant individuals. However, OUD remains a complex disease that comes with many serious health and legal concerns for both patients and clinicians. What do you know about OUD? Check your knowledge with this quick quiz. Despite pharmacologic treatment being known to be highly effective for treating OUD, a CDC report states that 30% of patients with OUD who require OUD treatment received only nonpharmacologic treatment. Further, 43% of patients did not perceive a need for OUD treatment at all. In this significant report, males aged 35-49 years were most likely to receive OUD treatment with medications, while females and younger and older adults had lower rates of access to pharmacologic interventions. The CDC concluded that engaging patients needing OUD treatment with pharmacologic interventions is 'essential.' Learn more about essential statistics for OUD. Data from a predictive-model study indicate that service setting was the strongest predictor for premature discontinuation of OUD treatment. The strength of this predictor declined with length of stay, becoming negligent after 365 days. Other system-level factors such as geographic region, primary source of payment for treatment, and referral source were also strong predictors of early discontinuation; individual factors such as age of first use, sex, and race were less predictive. Previous research cited by the study has also stressed the importance of reducing system-level barriers to care, and the updated federal guidance for opioid treatment programs have expanded access in several ways. Learn more about OUD guidance. Precipitated withdrawal can occur when transferring a patient from methadone to buprenorphine due to buprenorphine being only a partial opioid agonist; as such, the traditional method of transfer involves putting the patient in a controlled, moderate withdrawal state before initiating buprenorphine therapy. However, a novel dosing strategy called microinduction, which involves starting buprenorphine at submilligram doses (or 'low-dose induction'), and cross-tapering with methadone can prevent precipitated withdrawal. Additionally, this method is ideal for patients who want to switch from methadone to buprenorphine and those with chronic use of intravenous or intranasal fentanyl. A recent systematic review found that microinduction and traditional transfer methods had similar rates of successful induction of buprenorphine at 95.6%. Learn more about safe withdrawal practices for OUD. Both the CDC and the latest American Society of Addiction Medicine (ASAM) guidelines specifically state that pharmacotherapy for OUD should be offered as early as possible in pregnancy to prevent harms to both the patient and the fetus, noting that pharmacotherapy for OUD has been associated with improved maternal outcomes. ASAM specifically states, 'increasing the dose or split dosing is often required, especially in the third trimester.' Federal guidelines emphasize that pregnant individuals seeking treatment for OUD are considered a priority for enrollment in opioid treatment programs. Once receiving treatment, they do not generally recommended medically supervised withdrawal from pharmacotherapy for pregnant patients as it might harm the fetus and patient; further, ASAM guidelines state that patients who undergo medically supervised withdrawal are at an increased risk for 'return to opioid use.' However, if a patient decides to proceed with medically supervised withdrawal, ASAM guidelines suggest physicians provide education and resources regarding associated risks. The CDC also specifically recommends against abruptly discontinuing opioids during pregnancy, citing data and resources from the American College of Obstetricians and Gynecologists and the Substance Abuse and Mental Health Services Administration. Learn more about OUD. Federal guidelines specify that opioid treatment programs must conduct at least eight random drug tests per year on their patients. These tests must use FDA approved products that test for commonly abused substances that might affect patient safety, recovery, or adherence to OUD treatment. ASAM affirms this requirement, noting that many patients might need more frequent testing and that eight tests per year 'should be viewed as a minimum.' Learn more about drug testing in OUD. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns
RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

Yahoo

time31 minutes ago

  • Yahoo

RFK Jr.'s newest CDC vaccine panel includes critics of COVID shots, lockdowns

The Brief U.S. Health Secretary Robert F. Kennedy Jr. has replaced the government's vaccine advisory panel with eight new appointees. The new members include vocal critics of COVID-19 vaccines and pandemic lockdowns, such as Dr. Robert Malone and Dr. Martin Kulldorff. Public health groups have raised concerns that Kennedy's changes could undermine long-standing vaccination policies. NEW YORK - U.S. Health Secretary Robert F. Kennedy Jr. has named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. His selections include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. RELATED: RFK Jr. ousts entire CDC vaccine panel Kennedy made the announcement in a social media post on Wednesday. The backstory Kennedy's decision to "retire" the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. Dig deeper The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Big picture view The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. The Source The Associated Press contributed to this report. The information in this story comes from a social media announcement made by U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday, in which he introduced eight new members to the federal vaccine advisory panel. This story was reported from Los Angeles.

WTA to provide ranking protection for players pursuing fertility treatments
WTA to provide ranking protection for players pursuing fertility treatments

Washington Post

time36 minutes ago

  • Washington Post

WTA to provide ranking protection for players pursuing fertility treatments

In a move described as 'groundbreaking,' the WTA announced Wednesday it will provide rankings protection to players who take a break from the tour to undergo fertility procedures such as egg or embryo freezing. 'Having the protected ranking there, so that players don't feel forced to come back early and risk their health again,' 2017 U.S. Open champion Sloane Stephens said to the BBC Wednesday, 'is the best thing possible.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store